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Pharmacotherapy and Pregnancy: Highlights from the Third International
Conference for Individualized Pharmacotherapy in Pregnancy
David M. Haas, M.D., M.S.1,2, Beverly Gallauresi, M.P.H., R.N.3, Kristine Shields, M.S.N., M.P.H.4, Deborah Zeitlin, PharmD5, Shannon M.
Clark, M.D., M.M.S.6, Mary F. Hebert, PharmD7, Zhaoxia Ren, M.D., Ph.D.8, Srikanth C. Nallani, Ph.D.3, Eric M. Meslin, Ph.D.1,2,9, Karen B.
Feibus, M.D.3, Gideon Koren, M.D.10, W. Scott Goebel, M.D., Ph.D.1, Thomas Easterling, M.D.7, Scott C. Denne, M.D.1,2, David A. Flockhart,
M.D., Ph.D.1,2, and Jamie L. Renbarger, M.D., M.S.1,2
Abstract
To address provider struggles to provide evidence-based, rational drug therapy to pregnant women, this third Conference was convened
to highlight the current progress and research in the field. Speakers from academic centers, industry, and governmental institutions
spoke about: the Food and Drug Administration’s role in pregnancy pharmacology and the new labeling initiative; drug registries in
pregnancy; the pharmacist’s role in medication use in pregnancy; therapeutic areas such as preterm labor, gestational diabetes, nausea
and vomiting in pregnancy, and hypertension; breast-feeding and medications; ethical challenges for consent in pregnancy drug studies; the potential for cord blood banks; and concerns about the fetus when studying drugs in pregnancy. The Conference highlighted
several areas of collaboration within the current Obstetrics Pharmacology Research Units Network and hoped to educate providers,
researchers, and agencies with the common goal to improve the ability to safely and effectively use individualized pharmacotherapy in
pregnancy. Clin Trans Sci 2011; Volume 4: 204–209
Introduction

The use of medications in pregnancy is common and based
on complex risk-benefit discussions between physicians and
patients.1,2 Unfortunately, still there are deficits in the information
used in the decision making process. Often, pharmacokinetic
(PK) and pharmacodynamic (PD) information for drugs used in
pregnancy is scanty if present at all. A good example of that is the
recommendation about the use of oseltamivir for influenza. The
Centers for Disease Control and Prevention’s recommendation
states that no clinical studies have been conducted to assess the
safety of these medications for pregnant women. However, the
available risk-benefit data indicate pregnant women should receive
prompt therapy.3 This highlights the need for more data regarding
medication therapy in pregnancy. An annual Conference continues
to bring together leading researchers and representatives from
government agencies to discuss this matter.
The Third International Conference for Individualized
Pharmacotherapy in Pregnancy was convened in 2010. Bringing
together top researchers in the field, the Third Conference
focused on research and regulatory issues and objectives for
regulatory agencies as well as specific advances in several key
therapeutic areas. Below are the summaries of the discussions at
the conference. Full notes from the panel discussions are available
from the authors on request. Speaker video from the conference is
available at the PREGMED website: http://www.pregmed.org.
An Overview of the FDA Office of Women’s Health (OWH)
Funded Pregnancy Studies and Their Impact

The Food and Drug Administration’s (FDA) Office of Women’s
Health (OWH) was created in 1994 after the 1992 Government
Accounting Office report4 showed that women were not adequately

included in clinical studies. The FDA OWH mission is to (1) protect
and advance the health of women through policy, science, and
outreach, and (2) advocate for inclusion of women in clinical trials
and analysis of sex/gender effects. To that end from 2002 to 2010,
OWH has funded several studies to address hypertension, anthrax
prevention, depression, and infection during pregnancy.
The studies included: PKs and PDs of atenolol during pregnancy
and postpartum;5 the PK of amoxicillin during pregnancy and
postpartum;6 the PK and PD of sertraline in pregnancy and
postpartum;7 the PK and PD of labetalol in pregnancy; and the PK
and PD of selected antiinfective agents in pregnant women being
treated for suspected or documented infections. All studies were
conducted during the second and third trimesters of pregnancy.
Clearance for all drugs with the exception of azithromycin was
shown to increase during pregnancy. No data were available on
ciprofloxacin. Due to the limited number of subjects in the studies,
more data are needed in pregnant women.
Pregnancy Registries’ Contributions to Informed Clinical
Practice

Pregnancy registries are prospective active data-collection
systems that can facilitate the early detection of teratogenicity and
other serious adverse experiences in patients who inadvertently
or purposefully use a medication or receive a vaccine during
pregnancy. The use of the pregnancy registry design has allowed
for the collection and analysis of data on the effects of drug
exposure on human pregnancies that have otherwise been
difficult to obtain.8 Information from animal studies is useful but
not always applicable, and pregnant women rarely are enrolled in
clinical trials. However, useful information about the outcomes
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of exposed pregnancies can be obtained by the careful collection
and analysis of postmarketing surveillance data.
Pregnancy registries collect reports of exposure during
pregnancy and, through intensive follow-up with health care
providers and patients, obtain information about pregnancy
events and outcomes. Reports are evaluated and outcomes are
compared to rates in the background population and, if available,
in subpopulations with the relevant disease states. Reports of
birth defects are assessed for timing of exposure, maternal age
and medical history, biologic plausibility, etc. Voluntary reporting
is known to be subject to various biases and sample size is often
limited in pregnancy registries. Their strength lies in their ability
to obtain and analyze pregnancy outcomes early in the life of a
product and to evaluate patterns in birth-defect reports. Potential
birth-defect signals could then be evaluated in studies designed
for hypothesis testing.
The FDA encourages the establishment of pregnancy
registries for products intended for use by women of childbearing
potential in its “Guidance for Industry: Establishing Pregnancy
Exposure Registries”9 and maintains a list of active registries on
its website (http://www.fda.gov/ScienceResearch/SpecialTopics/
WomensHealthResearch/ucm134848.htm). Pregnancy registries
can provide periodic (semiannual or annual) summary reports that
are shared with regulatory agencies that monitor drug safety and
with health care professionals who request information about use
in pregnancy. Health care providers and patients who experience
a drug or vaccine exposure during pregnancy are encouraged to
request the summary reports and to enroll in pregnancy registries to
add to the existing data on medication safety during pregnancy.
On the Front Lines: A Pharmacist’s Perspective

Preliminary data from the National Center for Health Statistics
regarding 2008 birthrates show a decrease in live births, in 2008
compared to 2006. However, the live birth-rates per 1,000 women
increased from 9.4 (2006) to 9.9 (2008) in women 40 to 44 years
of age and 0.6 (2006) to 0.7 (2008) in women 45 to 49 years of
age.10,11 As women age, they are more likely to develop chronic
medical conditions. Treatment may start before conception. There
is a need to ensure optimal medication therapy prior to, during,
and after pregnancy to protect the mother and fetus from potential
side effects. These side effects may come from medications or
untreated conditions. When chronically hypertensive women
become pregnant, maintaining optimal blood pressure (BP) is the
primary goal, with antihypertensive agents if necessary.12 In an
asthmatic pregnancy, continuing current therapy does minimize
symptoms. Reinforcement of proper inhaler technique, medication
adherence, control of environmental allergens and coexisting
medical therapy, as well as smoking cessation, should also be
emphasized.13 Diabetics should have preconception counseling
to help maintain goal blood glucose levels throughout pregnancy.
A concern in depressed pregnant women is the potential for
complications if antidepressant therapy is discontinued. These
women should be advised to continue treatment for their benefit as
well as that of the fetus. Treatment includes appropriate nutrition
and weight gain, treatment of underlying addictions, improving
mood prior to conception, and routine follow-up.14
When assessing pregnant women with chronic medical
conditions, a risk/benefit exists regarding treatment to the patient
and the fetus.15 Pregnant women should be educated prior to
conception, to understand and weigh the risks of the complications
of their medical condition versus the side effects of treatment
and medications. Once a treatment decision is made, these
WWW.CTSJOURNAL.COM

patients should be monitored regularly to ascertain adherence
to appropriate treatment goals and should be encouraged to utilize
nonpharmacologic methods when appropriate.
A review of maternal/fetal considerations and pharmacotherapy
of tocolytics for preterm labor
In 2006, preterm birth (PTB) complicated 12.8% of pregnancies
in the United States, with 75% of these births resulting from
spontaneous preterm labor (PTL) and preterm premature rupture
of membranes.10 Long-term sequelae from PTB are more likely to
occur in neonates born before 32 weeks of gestation and/or weighing
less than 1,500 g. These sequelae include neurologic handicap,
blindness, deafness, and chronic respiratory disease. Acute tocolysis
of PTL is implemented in order to minimize maternal morbidity
and prolong pregnancy (≥48 hours) by allowing for administration
of glucocorticoids to hasten fetal lung maturity. Indomethacin,
nifedipine, and magnesium are three of the more commonly used
tocolytics. The use of tocolytic drugs should be individualized and
based on the maternal condition, potential for side effects, and fetal
gestational age.16 In addition, the physiologic changes of pregnancy
can affect the PK and PD of administered tocolytics, which may
alter the pharmacologic effect.
Indomethacin is an antiprostaglandin (PG) agent that inhibits
the synthesis of PGE2 and PGF2α—PGs known to be involved
in both term and PTL. Although prolonged indomethacin use
may be associated with vasoconstriction and persistent changes
in the fetal ductus arteriosus and the developing cerebral, renal,
and mesenteric circulations, it is the most common prostaglandin
inhibitor used for tocolysis. With a 50-mg loading dose, the peak
serum concentration of indomethacin is 2–3 mg/L, half-life (T1/2)
is 2.2 hours, plasma clearance is 0.044–0.109 L/h per kg, and volume
of distribution (Vd) is 0.34–1.57 L/kg.17 Indomethacin crosses the
placenta leading to fetal serum concentrations that are greater than
amniotic-fluid levels. Nifedipine is a calcium-channel antagonist
that induces vascular smooth muscle relaxation. Its absorption is
rapid, but bioavailability is low due to first-pass metabolism and
conversion of 40% of the drug into inactive metabolites.17,18 After
a 10-mg oral dose, the peak serum concentration is 38.6 ± 18 μg/L,
T1/2 is 1.3 ± 0.5 hours; and plasma clearance is 2.0 ± 0.8 L/h per kg.19
Nifedipine also crosses the placenta and is found in the umbilical
cord, fetal blood, and amniotic fluid. Although unlicensed and
with several contraindications to its use, including maternal side
effects, magnesium sulfate is commonly used for tocolysis in the
United States. Maternal serum concentrations do not correlate
with tocolytic effect, therefore, the infusion rate of magnesium
sulfate is titrated according to clinical response and side effects.20
With a 4-g intravenous loading dose of magnesium sulfate, the
peak serum concentration is 5.56 ± 0.30 mg/dL; T1/2 is 610 ±
14 minutes; and Vd is 15.6 L.17 Magnesium sulfate crosses the
placenta and is found in the amniotic fluid and fetal compartment.
Due to the limited amount of information available regarding
the appropriate dosing and frequency of administration of these
drugs, research into the PK and PD of tocolytics is necessary
in order to more effectively treat PTL and improve neonatal
outcomes through the prolongation of pregnancy.
How sweet it is—taking a second look at hypoglycemic agents
in pregnancy
Gestational diabetes mellitus affects nearly 18% of pregnancies
and is associated with significant maternal, fetal, and neonatal
complications. Oral hypoglycemic agents such as glyburide and
VOLUME 4 • ISSUE 3
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metformin are commonly used for the treatment of gestational
diabetes based on the randomized trials demonstrating similar
outcomes to insulin, in addition to their easy route of administration
and schedule.21,22 The physiologic changes that occur during
pregnancy such as alterations in CYP2C9, CYP3A, and CYP2C19
activities have been shown to alter the PK of glyburide, which may
have significant implications for the optimum dosage range during
pregnancy.23 However, glyburide has been shown to cross the
placenta, therefore, evaluation of alternate dosage regimens above
the currently used dosage range (up to 10 mg twice daily) will
need to consider fetal and neonatal safety.23 The changes in renal
filtration as well as active renal transport during pregnancy result
in altered PK of metformin.24 The changes may or may not result
in the need to alter the metformin dosage range during pregnancy.
In addition to considerations regarding dosage range optimization
for gestational diabetes mellitus treatment, medication selection
optimization requires further evaluation. The heterogeneity in
underlying abnormalities in insulin sensitivity and beta-cell
responsivity23 for women with gestational diabetes will likely
play a role in individual response to the various hypoglycemic
agents.
NIH update on pregnancy pharmacology programs
and the OPRUs
In the United States, more than 50% of women take one or more
medications during their pregnancies. But most of the medications
do not have adequate dosage and safety recommendations for the
pregnant women, which may adversely impact the health of both
pregnant women and their unborn babies. The Obstetric-fetal
Pharmacology Research Units (OPRU) network was funded by
the National Institute for Child Health and Human Development
in 2005 and was recompeted in 2009 to serve as a national resource
for pharmacologic studies of drug disposition and effect during
normal and abnormal pregnancies.
The OPRU network takes a multidisciplinary approach to
maternal and fetal therapeutics, pairing clinical and basic science
collaborative researchers within the sites and across the networks.
During the first funding cycle, the OPRUs performed a study on
glyburide’s effects during and after pregnancy23 and on the PKs
of 17alpha-hydroxyprogesterone caproate in pregnancy to reduce
the risk of recurrentPTB. The OPRU network also conducted
opportunistic studies to determine the PK of the drugs that are
being used for medications in women during their pregnancies.
The currently funded sites are Indiana University, University of
Pittsburgh, University of Texas Medical Branch in Galveston, and
University of Washington, along with a Data Coordinating Center
at Research Triangle International. Each site has unique clinical
and basic science strengths that synergize across the network
to be able to advance the field. In the current round of funding,
which began in 2010, there are currently two new clinical trials
moving forward: a trial of glyburide and metformin therapy for
gestational diabetes and a study of different progestins for the
prevention ofPTB.
Breast-feeding and medication in mother’s milk
Medications are commonly taken by women during pregnancy
and postpartum to treat diseases that are specifically related to
pregnancy or preexisting medical conditions. Just as ethical and
medical considerations are necessary for pharmacotherapy in
pregnancy, considerations are necessary to avoid the risk of drug
exposure to the infant by means of breast-milk transfer. Current206
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product labeling allows for the description of drug excretion to
human milk and discusses the risks for serious adverse events.
The case of the serious adverse event from codeine described by
Koren’s group highlights the importance of human and genetic
research in the area of human lactation.25 The FDA’s upcoming
pregnancy-labeling rule will include sections on risk summary,
clinical considerations, and known data. The most valuable study
data to help populate the new pregnancy label will come from
studies that look at the total infant exposure, measured by ratios
of areas under the concentration-time curve of drug in maternal
plasma as compared with breast milk. Clinical lactation studies
should be geared toward identifying the risk of drug exposures
to neonates, the total infant daily dose, and the safety and adverse
events due to drug exposure. While there is a paucity of this
type of data currently, more is on the way. With more data, it
will be possible to help nursing mothers and their physicians in
counseling and in planning clinical investigations.
Ethical challenges in consenting pregnant women
for medication research
Society’s approach to the protection of human subjects in
research might be captured best by the image of a slowly swinging
pendulum. In the early years (post-Nuremberg Code), a strong
protectionist ethic prevailed when concern about minimizing
risk was so pervasive that, to paraphrase Hans Jonas, society was
encouraged to accept slower progress in the conquest of disease
if it meant that human dignity and important moral values were
retained. As time passed and experience progressed, the absolutist
stance was relaxed, evidenced by the somewhat more permissive
Declaration of Helsinki that permitted (where Nuremberg did
not), research on vulnerable persons, including children. The
pendulum has rarely swung to a completely permissive (i.e., a
rule-free) position. But efforts to more carefully calibrate risk
and to define vulnerable populations in need of special additional
protections have been underway for decades. Pregnant women,
children, fetuses, and neonates are defined as “vulnerable” and in
need of additional protection according to this reasoning and have
at various times been either completely excluded from eligibility
for research or been limited participants. But here too, times have
changed and the pendulum has not remained static. The NIH
Policy and Guidelines on the Inclusion of Women and Minorities as
Subjects in Clinical Research—Amended October 200126 is a clear
statement on how to include vulnerable persons. Consistent with
the ethical principle of justice, the policy requires a justification
if these populations are to be excluded, suggesting that the
pendulum’s current trajectory has come to rest at a position of
moderate protectionism.
Medication research involving pregnant women may have
been previously discouraged, but not now. One reason for the
change in stance is the important role of informed consent as a
gatekeeper. No one questions the value of a robust consent process.
Where the challenges lie are at the level of quality and quantity
of information: how much information do researchers need to
disclose to subjects? Whereas it might seem self-evident that
patients should be given as much information as possible, some
research suggests that potential subjects do not actually understand
or want much of the information before making decisions. This
finding should give pause if applied to a medication study (do
we really want to give less rather than more information?), but,
in other areas such as the development of biobanks, changes
in the practice of informed consent are already underway.
WWW.CTSJOURNAL.COM
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Vanderbilt’s BioVU biobank is an opt-out system (not unlike
Spain’s presumed consent approach to organ transplantation)
where research subjects must indicate a preference not to have
data or information used in research.
The pendulum is also influenced by researchers serving in
multiple roles (e.g., health care provider and researcher), as do
many health care providers. As demonstrated in a recent study,
there is often a disconnect between what health care providers
will support for their patients and for themselves.27 Can we rely
on the quality of the data that help us inform decisions? If the
data are not robust, then are decisions truly informed? We also
know that research is not confined by national borders. Research
must also be sensitive to the social, political, and cultural issues
in different locations. For instance, in parts of Kenya, women
are culturally not allowed to consent for themselves. It is only
in discussing and working on these ethical challenges that
we can continue to see progress and meaningful and ethical
benefits to human subjects’ research in general, and specifically
in pregnancy.
FDA and Maternal Health Update: Gathering and Communicating Data about Drug Use during Pregnancy and
Lactation

There are more than 60 million American women of reproductive
age, and about 10% of them become pregnant each year, only
50% of these pregnancies are planned. Pregnant women may
require continued drug treatment for chronic conditions or
treatment for new conditions that arise during pregnancy. While
pregnant women use an average of four or five prescription drugs
during pregnancy, they are usually excluded from clinical drug
trials conducted prior to approval for marketing. Research and
knowledge gaps remain following FDA approval and marketing
of most drugs because studies of maternal and fetal effects and
the amount of drug in human milk are not routinely studied. In
turn, prescribers have little or no scientific evidence with which
to inform clinical care, prescribing, and counseling for women
of childbearing potential.
Over the past decade, new legislative authorities (FDA
Amendments Act of 2007), multiple FDA initiatives, and efforts
in the scientific and ethics communities have coalesced into
a movement to improve data gathering and communication
about drug use during pregnancy and lactation. The Pediatric
and Maternal Health Staff (PMHS) in the Office of New Drugs
at FDA’s Center for Drug Evaluation and Research focuses on
drug development and drug safety issues related to the use of
medications in children, adolescents, and women of childbearing
potential, especially those who are pregnant and breast-feeding.
FDA’s activities currently focus on three areas:
(1) Development, clearance, and publication of the final
regulations for pregnancy and lactation labeling for
prescription drugs and biological products.
(2) Development and publication of guidance for the drug
development industry and FDA reviewers (e.g., PK during
pregnancy and the postpartum period, clinical lactation
studies, pregnant women in clinical trials: scientific and
ethical considerations).
(3) Working with review divisions in the Office of New Drugs to
identify drugs that should be approved with requirements to
study the effects of the drug in pregnant women and/or the
amount of drug in human milk.
WWW.CTSJOURNAL.COM

The new proposed regulations for pregnancy and lactation
labeling for prescription drugs were published in May 2008. FDA
received comments on the proposed regulations during a 90-day
public comment period. These comments were considered and
utilized by the FDA in development of the final regulations for
publication, a process that is currently underway. The proposed
regulations call for eliminating the confusing and often misused
pregnancy categories (A, B, C, D, and X) from drug labeling for
all drugs and will revise the content and format of pregnancy
and nursing mothers labeling subsections for prescription
drugs approved on or after June 30, 2001. Drug manufacturers
will be able to voluntarily adopt the new format and content
requirements for older drugs. The pregnancy subsection
of labeling will include information about whether there is
an ongoing prospective cohort study (pregnancy exposure
registry) evaluating the effects of the drug in pregnant women
using the drug therapeutically. This will be followed by a Risk
Summary based on available human and animal data; a Clinical
Considerations section; and a Data section that includes detailed
information about the studies supporting the information in
the Risk Summary and Clinical Considerations. The Clinical
Considerations section provides information to prescribers to
support clinical decision making and management. It includes
information about the known risk to a pregnant woman and her
fetus from the disease or condition the drug is intended to treat,
dosing adjustments needed during pregnancy, maternal adverse
reactions unique to or exacerbated by pregnancy, and potential
neonatal complications and needed interventions. The Clinical
Considerations section also includes information about known
effects of the drug on labor and delivery.
FDA’s greatest communication tool is drug labeling, but
developing informed and balanced labeling is a complicated
and challenging process. This is especially true for information
about medication use during pregnancy and breast-feeding
because there is often limited information at the time that a
drug is approved. It is critical to our nation’s public health to
identify and communicate the risks and benefits of medication
treatment for mothers and their fetuses/infants. This can only be
accomplished with thorough scientific review of available human
and animal data, identification of ethical and scientifically sound
approaches to gathering more human data on medication use
during pregnancy and breast-feeding, and clear and clinically
relevant communication of this information to prescribers
through drug labeling.
New Frontiers in Nausea and Vomiting of Pregnancy

Nausea and vomiting of pregnancy (NVP) affects an estimated
80% of all pregnancies. The condition has been trivialized in
practice and research, assuming that it is merely an inconvenience.
However, research in Motherisk has shown major impact on the
quality of life of millions of women.28
Treatment of symptoms of NVP has been challenged by
limited research and less than optimal samples sizes to prove
fetal safety. The drug most studied has been the combination
of doxylamine and pyridoxine (vitamin B6). It is estimated that
this antiemetic combination will reenter the American market as
Diclectin® (a Canadian version of Bendectin®, used in the United
States until 1982). Recent studies have shown that NVP associated
with reflux symptoms is more severe, and that treatment of reflux
symptoms with either H2 blockers or Proton Pump Inhibitors
alleviates the severity of NVP.29
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207

Haas et al. Pharmacotherapy and Pregnancy
I

Cord blood (and tissue) banks—can they inform future
therapies?
Maternal and fetal/newborn tissues (e.g., cord blood, placenta)
are readily available, often discarded, and useful for both clinical
and research needs. There is potential for cord blood and tissue
banks to be repositories of cells and tissues for pharmacology
research. Areas in which cells/tissues are used for maternal/fetal
pharmacology research include transporter cellular/molecular
biology; growth factor production and signaling; enzyme
polymorphism studies; and drug metabolism studies. At the
present time, a variety of cell and tissue models, such as malignant
cell lines, isolated mature cells and/or microsomes, and ex vivo
perfused tissues are used for this research. However, the extent
to which these model systems represent normal maternal/fetal
tissues is unclear, and problems also exist with standardization
and reproducibility between laboratories. The use of primary
stem/progenitor cells derived from maternal/fetal tissues provides
potential solutions to some of these problems, since primary
cultures can be isolated using standardized techniques, greatly
expanded in culture, used to reproduce results using cells from
the same donor instead of multiple donors, and widely distributed
for validation of results in numerous laboratories.
The question remains regarding where these cells and tissues
would be processed for widespread research use. Cord blood
banks have been proposed as one potential source, since they
routinely process and store cord blood hematopoietic stem cells
for clinical use. However, cord blood banks perform minimal
cell isolation and no culture/expansion since there is currently
no clinical need for isolation and culture of hematopoietic cells,
and in general process only cord blood and not other maternal/
fetal tissues. Alternatively, tissue banks are well suited to providing
cells and tissues to the research community. Tissue banks can store
whole tissues but also isolate specific cells and often expand these
cells prior to (or after) banking. Primary cells from maternal/fetal
tissues that are potentially available from tissue banks include
mesenchymal stem cells (MSC) from cord blood, cord tissues
(e.g., Wharton’s jelly), and placenta; endometrial (or uterine)
regenerative cells (ERC); and human umbilical vein endothelial
cells (HUVEC). MSC are expandable in culture to >1012 cells
or >30 population doublings, facilitating multiple reproducible
experiments validated in many laboratories from a single donor.
Placental MSC have been demonstrated to participate in placental
tissue generation, maintenance, and repair, attesting to their utility
as a model for normal tissues. HUVEC are more limited in their
culture capacity than MSC and ERC, but are already widely used
for pharmacologic research, particularly involving oxidative stress
and vasogenic factors involved in pregnancy/labor. In summary,
primary cells provided by tissue banks from maternal and/or
neonatal tissues are readily available and expandable, are superior
to immortalized malignant cell lines, may be able to mimic in
vivo conditions by coculture of cell types (e.g., HUVEC with
placental MSC; maternal with fetal-derived MSC), and may be
amenable to additional manipulation, such as syncytialization
of trophoblasts in culture. Moreover, not only normal cells but
cells from neonates with genetic defects can be isolated; these
cells may provide additional cellular research models and disease
insights.
Preeclampsia and hypertension—individualizing therapy
Antihypertensive therapy in pregnancy and preeclampsia have
evolved as the data have driven more individualization. The risk
208
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of not intervening is severe hypertension and its adverse maternal
sequelae. The risk of intervening too early is premature or small
for gestational age babies. It is evident that treating hypertension
in pregnancy prevents severe hypertensive crises.30
Individualizing therapy based on maternal hemodynamics is
based on the equation that Mean Arterial Pressure (MAP) = Cardiac
Output (CO) × Total Peripheral Resistance (TPR)/80. In order to
control blood pressure, either the CO or TPR can be targeted by
therapy. Additionally, simply because the majority of hypertensive
pregnant women are in a vasoconstricted state does not mean that
all subjects would benefit from lowering resistance. Studies have
demonstrated that controlling BP before women get pregnant
can reduce preterm deliveries. A small study demonstrated that
atenolol therapy led to smaller babies.31 It is confirmed that there is
a trade-off that as the BP is lowered, the birth weight does go down,
however, there is less preterm delivery and respiratory distress
syndrome. Individualizing therapy may actually indicate that it
takes less drugs to control the BP as the pregnancy progresses.
Hydralazine is a vasodilator that leads to a small increase in CO
as the MAP decreases. Beta blockers such as atenolol decrease
CO, leading to a decrease in MAP and a slight increase in TPR.
Diuretics such as furosamide decrease CO in smaller amounts than
beta blockers. Clonidine is a complex drug that has considerable
variability in CO and TPR response. Thus, combination therapy
can often achieve the normalization of maternal hemodynamic
parameters that single-agent therapy is unable to provide. Individual
variation in drug metabolizing enzymes may also play a role as
certain drugs such as metoprolol are CYP2D6 substrates and can
have profound differences in activities throughout pregnancy.
The goal of the PK and PD principles in fostering individualized
drug therapy for hypertension and preeclampsia is to promote
maternal health, prevent PTB, and maintain fetal growth. Maternal
hemodynamics can be used to effectively direct therapy to achieve
these individualized pharmacotherapy goals.
Do not forget the baby—studying neonatal effects of drugs
in pregnancy
Fetal development is an especially sensitive period, and
alterations and interventions have the potential to produce
lifelong consequences. As predicted by the fetal origins of adult
disease hypothesis, it is becoming increasingly clear that altered
fetal growth can significantly increase the risk of adult onset
diseases such as hypertension, coronary artery disease, and type
II diabetes. It is then reasonable to be concerned that maternal
exposure to drugs may have the potential to produce similar
long-term consequences.
The use of antenatal steroids to reduce respiratory distress
syndrome in premature infants is probably the best-studied
fetal drug exposure. Multiple randomized controlled trials
have demonstrated that antenatal steroids provide significant
benefits, including reductions in respiratory-distress syndrome,
intraventricular hemorrhage, necrotizing enterocolitis, and death.
In addition, there is significant information about the effects
of antenatal steroids beyond the neonatal period. Exposure to
antenatal steroids has no detrimental effect in children or adults
on hypothalamic pituitary axis function, growth, blood pressure,
or cholesterol concentrations. There is even a suggestion that
blood-glucose concentrations may be lower in adults who have
received antenatal steroids compared to those who have not. So
for antenatal steroids, there is high-quality evidence supporting
significant neonatal benefits and no long-term negative effects;
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it is unlikely that this amount or quality of information will be
produced for most other maternal drug exposures.
A drug class of current interest is the selective serotonin
reuptake inhibitors (SSRIs). There are no available randomizedcontrolled trials, but observational studies have raised concerns
about SSRI exposure and increased risk of premature delivery,
although untreated depression may have a similar effect.
Neonatal-abstinence syndrome after in utero exposure to SSRIs
has been well documented, with approximately 30% of exposed
infants having symptoms. A relationship between maternal use
of SSRIs and persistent pulmonary hypertension of the newborn
has also been observed; however, the increase in risk appears
to be small, and not all studies have observed the relationship.
Observational studies examining neurodevelopmental outcome
after maternal use of SSRIs have not measured any adverse
effects in children up to 6 years of age. However, the effects of
fetal SSRI exposure beyond early childhood remain unknown.
Some mechanism to evaluate the long-term effects of drugs in
pregnancy is necessary; as electronic medical records become
more prevalent, documenting maternal drug exposures in the
medical record would be an important advance in evaluating
long-term drug effects in children and the mothers.
Conclusion

As providers, pharmacists, FDA and NIH representatives, and
patients make decisions every day about medication therapy in
pregnancy, it is clear that more data are needed. Hypertension,
diabetes, and PTL are just a few of the conditions that require
drug therapy in pregnancy. Understanding the data through the
current research, and upcoming pregnancy and lactation labeling
changes, will aid in counseling pregnant women about their
options. Cooperation and collaboration between government
agencies, researchers, and people on the front lines of patient care
will continue to strive to improve the care of pregnant women
and their babies.
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